



# Insights from Stem Cell Therapy Developers

At ISSCR\* 2026, we captured the voice of 64 members of the stem cell therapy community through an on-site survey of researchers, developers, and manufacturing experts. This infographic highlights the key results and offers a snapshot of the priorities, pain points, and decisions driving cell therapy production.

## Respondent Profile




\*This survey was not conducted, endorsed, or sponsored by ISSCR.

## Where the friction lives

Respondents weigh in on the toughest barriers in stem cell R&D through translation




 Respondents weigh the impact of purity-related risks on development and manufacturing.



Though respondents have various views on the greatest purity-related risk, most respondents selected adventitious agents as their first or second choice.

 Respondents rank the top challenges in demonstrating and maintaining potency.




\*\*Adventitious agents are defined as unintended microorganisms (such as viruses, bacteria, fungi, mycoplasma, or prions) that contaminate cell cultures, raw materials, or biological products during the manufacturing process.

## Choices and paths to scale

Respondents compare priorities from research bench to clinical-stage manufacturing.

 **Priorities for raw material selection**  
Research and early development vs. Clinical-stage manufacturing



Across all phases from early development through translation to clinical evaluation, survey participants consistently identified product quality and consistency as top priorities, with regulatory considerations becoming increasingly important as products advance toward the clinic.

 Respondents share their view on top challenges when scaling from research to manufacturing.

